Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial

Ixazomib is an effective oral proteasome inhibitor with favorable toxicity profile. Recent studies showed significant activity as single agent with dexamethasone and in combination with other agents. Here, we evaluate the activity and tolerability of the all-oral combination ixazomib-thalidomide-dexamethasone (IxaThalDex) in pts with RRMM.